Frank Friedlos

4.0k total citations
59 papers, 3.2k citations indexed

About

Frank Friedlos is a scholar working on Molecular Biology, Genetics and Organic Chemistry. According to data from OpenAlex, Frank Friedlos has authored 59 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 19 papers in Genetics and 18 papers in Organic Chemistry. Recurrent topics in Frank Friedlos's work include Virus-based gene therapy research (19 papers), Cancer Research and Treatments (13 papers) and Click Chemistry and Applications (9 papers). Frank Friedlos is often cited by papers focused on Virus-based gene therapy research (19 papers), Cancer Research and Treatments (13 papers) and Click Chemistry and Applications (9 papers). Frank Friedlos collaborates with scholars based in United Kingdom, United States and New Zealand. Frank Friedlos's co-authors include Richard J. Knox, J. J. Roberts, Caroline J. Springer, Richard Marais, David Lydall, Dan Niculescu‐Duvaz, Marion P. Boland, Roger F. Sherwood, Lawrence Davies and Roger G. Melton and has published in prestigious journals such as Nucleic Acids Research, Cancer Research and Oncogene.

In The Last Decade

Frank Friedlos

59 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank Friedlos United Kingdom 30 2.2k 942 688 602 566 59 3.2k
Richard J. Knox United Kingdom 33 1.8k 0.8× 641 0.7× 924 1.3× 421 0.7× 449 0.8× 64 3.1k
David Heimbrook United States 34 3.0k 1.4× 2.3k 2.4× 369 0.5× 397 0.7× 295 0.5× 69 4.6k
Mary K. Danks United States 39 3.4k 1.6× 2.0k 2.1× 503 0.7× 420 0.7× 191 0.3× 99 5.0k
Jeff B. Smaill New Zealand 30 1.9k 0.9× 1.0k 1.1× 1.0k 1.5× 190 0.3× 320 0.6× 95 3.4k
Angelika M. Burger United States 37 2.7k 1.3× 981 1.0× 491 0.7× 236 0.4× 150 0.3× 81 4.1k
Mian M. Alauddin United States 31 1.2k 0.5× 693 0.7× 457 0.7× 728 1.2× 249 0.4× 109 3.4k
Pascal Verdier‐Pinard United States 32 2.2k 1.0× 1.1k 1.2× 1.3k 1.8× 172 0.3× 257 0.5× 60 4.1k
Archie W. Prestayko United States 25 1.8k 0.8× 947 1.0× 392 0.6× 167 0.3× 188 0.3× 50 3.0k
Ralph J. Bernacki United States 38 2.4k 1.1× 1.3k 1.4× 1.1k 1.5× 107 0.2× 252 0.4× 128 4.0k
Adam V. Patterson New Zealand 41 2.7k 1.3× 1.0k 1.1× 664 1.0× 652 1.1× 849 1.5× 154 5.2k

Countries citing papers authored by Frank Friedlos

Since Specialization
Citations

This map shows the geographic impact of Frank Friedlos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Friedlos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Friedlos more than expected).

Fields of papers citing papers by Frank Friedlos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Friedlos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Friedlos. The network helps show where Frank Friedlos may publish in the future.

Co-authorship network of co-authors of Frank Friedlos

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Friedlos. A scholar is included among the top collaborators of Frank Friedlos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Friedlos. Frank Friedlos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Niculescu‐Duvaz, Dan, Ion Niculescu‐Duvaz, Bart M. J. M. Suijkerbuijk, et al.. (2010). Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds. Bioorganic & Medicinal Chemistry. 18(18). 6934–6952. 28 indexed citations
2.
Mancini, Laura, Lawrence Davies, Frank Friedlos, et al.. (2009). A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy. NMR in Biomedicine. 22(5). 561–566. 8 indexed citations
3.
Schepelmann, Silke, Robert A. Spooner, Frank Friedlos, & Richard Marais. (2004). Methods to Improve Efficacy in Suicide Gene Therapy Approaches: Targeting Prodrug-Activating Enzymes Carboxypeptidase G2 and Nitroreductase to Different Subcellular Compartments. Humana Press eBooks. 90. 279–302. 4 indexed citations
4.
Karasarides, Maria, Antonio Chiloeches, Robert Hayward, et al.. (2004). B-RAF is a therapeutic target in melanoma. Oncogene. 23(37). 6292–6298. 360 indexed citations
5.
Friedlos, Frank, Stephen M. Stribbling, Jean‐Christian Roussel, et al.. (2003). A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. British Journal of Cancer. 88(10). 1622–1630. 11 indexed citations
6.
Spooner, Robert A., et al.. (2001). Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy. International Journal of Cancer. 93(1). 123–130. 12 indexed citations
7.
McNeish, Iain A., Stephen M. Roberts, Rachel Kerr, et al.. (1998). Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954. British Journal of Cancer. 78. 155–156. 2 indexed citations
9.
Wyatt, Michael D., et al.. (1997). Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. British Journal of Cancer. 76(12). 1596–1603. 27 indexed citations
10.
Knox, Richard J., Frank Friedlos, Michael Jarman, et al.. (1995). Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochemical Pharmacology. 49(11). 1641–1647. 29 indexed citations
11.
Knox, Richard J., Frank Friedlos, Patrick J. Biggs, et al.. (1993). Identification, synthesis and properties of 5-(aziridin-1-YL)-2-nitro-4-nitrosobenzamide, A novel DNA crosslinking agent derived from CB1954. Biochemical Pharmacology. 46(5). 797–803. 23 indexed citations
12.
Knox, Richard J., Frank Friedlos, & Marion P. Boland. (1993). The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer and Metastasis Reviews. 12(2). 195–212. 87 indexed citations
13.
Friedlos, Frank, Michael Jarman, Lawrence Davies, Marion P. Boland, & Richard J. Knox. (1992). Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochemical Pharmacology. 44(1). 25–31. 41 indexed citations
14.
Melton, Roger G., et al.. (1992). The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—I. Biochemical Pharmacology. 44(12). 2289–2295. 183 indexed citations
17.
18.
Knox, R.J., David Lydall, Frank Friedlos, Connie Basham, & J. J. Roberts. (1987). The effect of monofunctional or difunctional platinum adducts and of various other associated DNA damage on the expression of transfected DNA in mammalian cell lines sensitive or resistant to difunctional agents. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 908(3). 214–223. 24 indexed citations
19.
Roberts, J. J. & Frank Friedlos. (1987). Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: Relationship to toxicity. Pharmacology & Therapeutics. 34(2). 215–246. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026